Trial Profile
Multicenter Study for the Evaluation of Efficacy and Safety of NeoRecormon® Therapy Administered as 30000 IU Subcutaneously in Anemic Patients With Breast Cancer Treated With Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2018
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Therapeutic Use
- Sponsors Roche
- 06 May 2016 New trial record